Truist Financial analyst Richard Newitter maintains $Medtronic (MDT.US)$ with a hold rating.
According to TipRanks data, the analyst has a success rate of 59.1% and a total average return of 16.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Medtronic (MDT.US)$'s main analysts recently are as follows:
While the FY25 high-single-digit EPS growth exit rate offers a positive outlook, the company will face challenges such as ongoing FX pressures, potentially dilutive new product rollouts, and a slight tax issue heading into FY26, which are expected to restrain a sustainable return to high single-digit EPS growth.
The company reported a Q2 revenue exceedance, fueled by performance in cardiovascular, neurology, and diabetes sectors. Additionally, Medtronic has increased its FY25 guidance to between 4.75%-5.0%. Moving into FY26, it is anticipated that EPS growth may surpass overall revenue growth.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
